Reliq Health Announces Closing of Oversubscribed Non-Brokered Private Placement with Gravitas Securities as Exclusive Financial Advisors
Each Unit each consists of one (1) common share (the “Common Share“) and one half (1/2) transferrable share purchase warrant (the “Warrant“). Each of the 3,468,600warrants entitles the holder thereof to purchase one (1) additional Common Share on or before June 21, 2019 at a price of CDN$0.165 per Common Share.
“We’re very pleased to complete a successful oversubscribed offering,” said Dr. Lisa Crossley, CEO of Reliq. “Gravitas played an instrumental role in the success of the private placement as exclusive advisor.”
In accordance with the policies of the TSX Venture Exchange, the Company paid Finders’ Fees of an aggregate of $61,047.36 in cash and an aggregate of 554,976 finder warrants (the “Finder Warrant“). Each Finder Warrant will entitle the holder thereof to purchase one (1) additional Common Share on or before June 21, 2019 at a price of CDN$0.165per Common Share.
The securities issued are subject to a 4 month hold period that expires on October 22, 2017.
About Gravitas Securities Inc.
Gravitas is known for sophisticated sector expertise, tactical individuals with a commitment to excellence, global integration and innovation, and as a leading independent wealth management and capital markets firm. Gravitas provides a wide range of investment mandates and services for retail and corporate clients globally from offices in Toronto, Vancouver, and Calgary, and is represented in the United States through its FINRA representative, Gravitas Capital International, in New York and San Francisco.
ON BEHALF OF THE BOARD
Dr. Lisa Crossley, CEO and Director
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statements Regarding Forward Looking Information
Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.
We caution you that such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.
Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including technology development, anticipated revenues, projected size of market, and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.
Reliq Health Technologies Inc. (the “Company“) does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, technology development and marketing activities, the Company’s historical experience with technology development, uninsured risks. Actual results may differ materially from those expressed or implied by such forward-looking statements.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
